OLIGOPELVIS 2-GETUG P12:前列腺癌寡复发盆腔/腹主动脉旁淋巴结选择性淋巴结放疗的早期毒性
OLIGOPELVIS-2/GETUG P12 是一项前瞻性多中心随机III期试验,评估挽救性选择性淋巴结放疗(ENRT)联合间歇性雄激素剥夺治疗(iADT)对比单用iADT在前列腺癌盆腔及腹主动脉旁寡转移患者中的18个月毒性。共256例患者入组,安全性人群为A组127例、B组121例。结果显示ENRT联合iADT的18个月毒性可接受,既往前列腺或前列腺床放疗及额外腹主动脉旁放疗未显著增加毒性。
要点
- ENRT联合iADT在18个月时≥2级泌尿生殖毒性为10.7%,胃肠道毒性无差异。
- 6个月时ENRT组≥2级泌尿生殖和胃肠道毒性均高于单用iADT组。
- 既往前列腺或前列腺床放疗未增加任何时间点的毒性。
核心结论
- 挽救性ENRT联合病理淋巴结同步加量与6个月iADT的18个月毒性可接受,即使患者既往接受过前列腺放疗或额外腹主动脉旁放疗。
研究设计与样本
- OLIGOPELVIS-2/GETUG P12为前瞻性、多中心、随机III期试验,2018年12月至2023年5月在17家法国中心入组256例患者。
- 患者1:1随机至A组(6个月iADT单用)或B组(6个月iADT+ENRT:盆腔淋巴结54 Gy/1.8 Gy每次,病理淋巴结66 Gy/2.2 Gy每次),ENRT在iADT三个月后开始。
- 安全性人群包括A组127例和B组121例,B组8例因最终未接受放疗被排除。
- 2021年12月22日修正案允许纳入腹主动脉旁淋巴结并将照射野延伸至肾动脉。
- 毒性采用NCI-CTCAE v4.0定义。
主要发现
- 6个月时,A组与B组≥2级泌尿生殖毒性分别为2.4% vs 9.9%(p=0.02),胃肠道毒性分别为0% vs 19.8%(p<0.001)。
- 18个月时,A组与B组≥2级泌尿生殖毒性分别为4.1% vs 10.7%(p=0.04),胃肠道毒性无差异。
- B组中39例同时接受腹主动脉旁放疗;与未接受者相比,6个月≥2级毒性相似(泌尿生殖:12.8% vs 8.5%,p=0.8;胃肠道:20.5% vs 19.5%,p=0.9),18个月亦相似(泌尿生殖:10.3% vs 11%,p=1.0;胃肠道:0% vs 6.1%,p=0.17)。
- 接受腹主动脉旁放疗者6个月≥1级上消化道疾病更频繁(25.6% vs 9.8%,p=0.02)。
- 既往前列腺或前列腺床放疗分别见于57%和55%的患者,未增加任何时间点的毒性。
关键数值与推荐
- ENRT剂量:盆腔淋巴结54 Gy/1.8 Gy每次,病理淋巴结66 Gy/2.2 Gy每次。
- iADT疗程为6个月,ENRT在iADT三个月后开始。
- 毒性分级采用NCI-CTCAE v4.0。
临床怎么用
- 对前列腺癌盆腔及腹主动脉旁寡复发淋巴结转移患者,可考虑挽救性ENRT联合6个月iADT,需告知6个月时泌尿生殖和胃肠道毒性增加但18个月时可接受。
- 既往前列腺或前列腺床放疗史不应作为ENRT的绝对禁忌。
- 腹主动脉旁放疗可考虑纳入照射野,但需关注6个月上消化道不良反应。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: /objective: Limited pelvic/para-aortic nodal relapse of prostate cancer after radical local treatment remains a major challenge for locoregional salvage strategies. Salvage Elective Nodes radiotherapy (ENRT) is an appealing option, but concerns persist regarding its toxicity. This study evaluates the 18-months toxicity profile of salvage ENRT combined with intermittent androgen deprivation therapy (iADT) in patients with pelvic and para-aortic oligometastatic disease, compared with iADT alone. MATERIAL: /Methods: OLIGOPELVIS-2/GETUG P12 was a prospective, multicenter, randomized phase III trial. Patients were randomized 1:1 to arm A (6-months iADT alone) or arm B (6-months iADT + ENRT: 54 Gy/1.8 Gy per fraction to the pelvic lymph nodes and 66 Gy/2.2 Gy per fraction to pathological nodes). ENRT started after three months of iADT. After analyzing relapse patterns in the OLIGOPELVIS GETUG P07 study, a December 22, 2021 amendment permitted the inclusion of para-aortic lymph nodes and extended irradiation fields up to the renal arteries. Toxicity was defined using NCI-CTCAE v4.0. RESULTS: A total of 256 patients were enrolled across 17 French centers between 12/2018 and 05/2023. The safety population included 127 patients in arm A and 121 in arm B. Eight patients in arm B were excluded as they did not ultimately receive radiotherapy. Prior prostate or prostatic bed irradiation was reported in 57% and 55% of patients, respectively. In arm B, 39 patients also received para-aortic irradiation. At 6 months, grade ≥ 2 genitourinary (GU) and gastrointestinal (GI) toxicities occurred in 2.4% vs 9.9% (p = 0.02) and 0% vs 19.8% (p < 0.001) of patients in arms A and B, respectively. At 18 months, grade ≥ 2 GU toxicity was 4.1% vs 10.7%, (p = 0.04) in arms A and B, respectively, while no difference in GI toxicity was observed. Prior prostate or prostatic bed irradiation did not increase toxicity at any time point. Among patients receiving para-aortic irradiation, compared to those without : grade ≥ 2 toxicity was similar at 6 months (GU: 12.8% vs 8.5%, p = 0.8; GI: 20.5% vs 19.5%, p = 0.9), or at 18 months (GU: 10.3% vs 11%, p = 1.0; GI: 0% vs 6.1%, p = 0.17), though 6 months upper grade ≥ 1 GI disorders were more frequent (25.6% vs 9.8%, p = 0.02). CONCLUSIONS: Eighteen-month toxicity of salvage ENRT with a simultaneous boost to the pathological lymph nodes, associated with 6-months iADT was acceptable, even among patients with prior prostate irradiation or additional para-aortic irradiation (NCT03630666- RCB 2018-A00551-54; FundingPHRC-K 16-129).
引用
- Corda H, Blanc-Lapierre A, Pigne G, et al. OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial. Radiother Oncol. 2026. PMID: 42140755. doi:10.1016/j.radonc.2026.111533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。